Effect of bariatric surgery on heart failure

References

• Ogden CL, Carroll MD, Kit BK, et al. Prevalence of obesity among adults: United States, 2011-2012. NCHS Data Brief. 2013;(131):1–8. Available from: https://www.cdc.gov/nchs/data/databriefs/db131.pdf.
   Google Scholar
• Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation. 2009;120:86–95.
   PubMed Web of Science ®Google Scholar
• Lewis CE, McTigue KM, Burke LE, et al. Mortality, health outcomes, and body mass index in the overweight range: a science advisory from the American Heart Association. Circulation. 2009;119:3263–3271.
   PubMed Web of Science ®Google Scholar
• Roger VL, Go AS, Lloyd-Jones DM, et al. Executive summary: heart disease and stroke statistics–2012 update: a report from the American Heart Association. Circulation. 2012;125:188–197.
   PubMed Web of Science ®Google Scholar
• Rheaume C, Leblanc ME, Poirier P. Adiposity assessment: explaining the association between obesity, hypertension and stroke. Expert Rev Cardiovasc Ther. 2011;9:1557–1564.
   PubMedGoogle Scholar
• Bastien M, Poirier P, Lemieux I, et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis. 2014;56:369–381.
   PubMed Web of Science ®Google Scholar
• Poirier P, Cornier MA, Mazzone T, et al. Bariatric surgery and cardiovascular risk factors: a scientific statement from the American Heart Association. Circulation. 2011;123:1683–1701.
   PubMed Web of Science ®Google Scholar
• Cornier MA, Despres JP, Davis N, et al. Assessing adiposity: a scientific statement from the American Heart Association. Circulation. 2011;124:1996–2019.
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Petrie MC, Murdoch DR, et al. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl):P:9-16.
   Google Scholar
• Teng TH, Finn J, Hobbs M, et al. Heart failure: incidence, case fatality, and hospitalization rates in Western Australia between 1990 and 2005. Circ Heart Fail. 2010;3:236–243.
   PubMed Web of Science ®Google Scholar
• Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347:1397–1402.
   PubMed Web of Science ®Google Scholar
• Stevens GA, Singh GM, Lu Y, et al. National, regional, and global trends in adult overweight and obesity prevalences. Popul Health Metr. 2012;10:22.
   PubMed Web of Science ®Google Scholar
• Schocken DD, Benjamin EJ, Fonarow GC, et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation. 2008;117:2544–2565.
   PubMed Web of Science ®Google Scholar
• Kenchaiah S, Evans JC, Levy D, et al. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305–313.
   PubMed Web of Science ®Google Scholar
• Alpert MA, Terry BE, Mulekar M, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997;80:736–740.
   PubMed Web of Science ®Google Scholar
• Aune D, Sen A, Norat T, et al. Body mass index, abdominal fatness, and heart failure incidence and mortality: a systematic review and dose-response meta-analysis of prospective studies. Circulation. 2016;133:639–649.
   PubMed Web of Science ®Google Scholar
• Bazzano LA, Belame SN, Patel DA, et al. Obesity and left ventricular dilatation in young adulthood: the Bogalusa Heart Study. Clin Cardiol. 2011;34:153–159.
   PubMed Web of Science ®Google Scholar
• Shah RV, Abbasi SA, Heydari B, et al. Insulin resistance, subclinical left ventricular remodeling, and the obesity paradox: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2013;61:1698–1706.
   PubMed Web of Science ®Google Scholar
• Yeboah J, Bluemke DA, Hundley WG, et al. Left ventricular dilation and incident congestive heart failure in asymptomatic adults without cardiovascular disease: multi-ethnic study of atherosclerosis (MESA). J Card Fail. 2014;20:905–911.
   PubMed Web of Science ®Google Scholar
• Waring ME, Saczynski JS, McManus D, et al. Weight and mortality following heart failure hospitalization among diabetic patients. Am J Med. 2011;124:834–840.
   PubMed Web of Science ®Google Scholar
• Curtis JP, Selter JG, Wang Y, et al. The obesity paradox: body mass index and outcomes in patients with heart failure. Arch Intern Med. 2005;165:55–61.
   PubMed Web of Science ®Google Scholar
• Hu G, Jousilahti P, Antikainen R, et al. Joint effects of physical activity, body mass index, waist circumference, and waist-to-hip ratio on the risk of heart failure. Circulation. 2010;121:237–244.
   PubMed Web of Science ®Google Scholar
• Clark AL, Fonarow GC, Horwich TB. Waist circumference, body mass index, and survival in systolic heart failure: the obesity paradox revisited. J Card Fail. 2011;17:374–380.
   PubMed Web of Science ®Google Scholar
• Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association scientific statement on obesity and heart disease from the obesity committee of the council on nutrition, physical activity, and metabolism. Circulation. 2006;113:898–918.
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Alpert MA, Arena R, et al. Impact of obesity and the obesity paradox on prevalence and prognosis in heart failure. JACC Heart Fail. 2013;1:93–102.
   PubMed Web of Science ®Google Scholar
• Kuperstein R, Hanly P, Niroumand M, et al. The importance of age and obesity on the relation between diabetes and left ventricular mass. J Am Coll Cardiol. 2001;37:1957–1962.
   PubMed Web of Science ®Google Scholar
• Lauer MS, Evans JC, Levy D. Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol. 1992;70:1180–1184.
   PubMed Web of Science ®Google Scholar
• Aurigemma GP, Zile MR, Gaasch WH. Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation. 2006;113:296–304.
   PubMed Web of Science ®Google Scholar
• Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–259.
   PubMed Web of Science ®Google Scholar
• Bursi F, Weston SA, Redfield MM, et al. Systolic and diastolic heart failure in the community. Jama. 2006;296:2209–2216.
   PubMed Web of Science ®Google Scholar
• Lee DS, Gona P, Vasan RS, et al. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119:3070–3077.
   PubMed Web of Science ®Google Scholar
• Lenzen MJ, Scholte Op Reimer WJ, Boersma E, et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the Euroheart failure survey. Eur Heart J. 2004;25:1214–1220.
   PubMed Web of Science ®Google Scholar
• Gaasch WH, Zile MR. Left ventricular diastolic dysfunction and diastolic heart failure. Annu Rev Med. 2004;55:373–394.
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of co-morbidities in heart failure. Eur J Heart Fail. 2016;18:744–758.
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart failure and echocardiography associations of the European society of cardiology. Eur Heart J. 2007;28:2539–2550.
   PubMed Web of Science ®Google Scholar
• Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: a community-based study in an elderly cohort. J Am Coll Cardiol. 2011;57:1368–1374.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Quesada C, Cavalera M, Biernacka A, et al. Thrombospondin-1 induction in the diabetic myocardium stabilizes the cardiac matrix in addition to promoting vascular rarefaction through angiopoietin-2 upregulation. Circ Res. 2013;113:1331–1344.
   PubMed Web of Science ®Google Scholar
• Cavalera M, Wang J, Frangogiannis NG. Obesity, metabolic dysfunction, and cardiac fibrosis: pathophysiological pathways, molecular mechanisms, and therapeutic opportunities. Transl Res. 2014;164:323–335.
   PubMed Web of Science ®Google Scholar
• Zhi H, Luptak I, Alreja G, et al. Effects of direct Renin inhibition on myocardial fibrosis and cardiac fibroblast function. PLoS One. 2013;8:e81612.
   PubMed Web of Science ®Google Scholar
• Schorb W, Booz GW, Dostal DE, et al. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res. 1993;72:1245–1254.
   PubMed Web of Science ®Google Scholar
• Sadoshima J, Izumo S. Molecular characterization of angiotensin II–induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res. 1993;73:413–423.
   PubMed Web of Science ®Google Scholar
• Crabos M, Roth M, Hahn AW, et al. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest. 1994;93:2372–2378.
   PubMed Web of Science ®Google Scholar
• Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62:263–271.
   PubMed Web of Science ®Google Scholar
• Belin de Chantemele EJ, Mintz JD, Rainey WE, et al. Impact of leptin-mediated sympatho-activation on cardiovascular function in obese mice. Hypertension. 2011;58:271–279.
   PubMed Web of Science ®Google Scholar
• Konishi M, Sugiyama S, Sugamura K, et al. Accumulation of pericardial fat correlates with left ventricular diastolic dysfunction in patients with normal ejection fraction. J Cardiol. 2012;59:344–351.
   PubMed Web of Science ®Google Scholar
• Goodwin GW, Taylor CS, Taegtmeyer H. Regulation of energy metabolism of the heart during acute increase in heart work. J Biol Chem. 1998;273:29530–29539.
   PubMed Web of Science ®Google Scholar
• How OJ, Aasum E, Kunnathu S, et al. Influence of substrate supply on cardiac efficiency, as measured by pressure-volume analysis in ex vivo mouse hearts. Am J Physiol Heart Circ Physiol. 2005;288:H2979–H2985.
   PubMed Web of Science ®Google Scholar
• Rider OJ, Cox P, Tyler D, et al. Myocardial substrate metabolism in obesity. Int J Obes (Lond). 2013;37:972–979.
   PubMed Web of Science ®Google Scholar
• Turer AT, Hill JA, Elmquist JK, et al. Adipose tissue biology and cardiomyopathy: translational implications. Circ Res. 2012;111:1565–1577.
   PubMed Web of Science ®Google Scholar
• Horwich TB, Fonarow GC. Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure. J Am Coll Cardiol. 2010;55:283–293.
   PubMed Web of Science ®Google Scholar
• Ebong IA, Goff DC Jr., Rodriguez CJ, et al. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014;8:e540–e548.
   PubMed Web of Science ®Google Scholar
• Wong C, Marwick TH. Obesity cardiomyopathy: pathogenesis and pathophysiology. Nat Clin Pract Cardiovasc Med. 2007;4:436–443.
   PubMedGoogle Scholar
• Banerjee S, Peterson LR. Myocardial metabolism and cardiac performance in obesity and insulin resistance. Curr Cardiol Rep. 2007;9:143–149.
   PubMedGoogle Scholar
• Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14:281–287.
   PubMed Web of Science ®Google Scholar
• Iacobellis G. Epicardial and pericardial fat: close, but very different. Obesity (Silver Spring). 2009;17:625–627.
   PubMed Web of Science ®Google Scholar
• Szczepaniak LS, Dobbins RL, Metzger GJ, et al. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Magn Reson Med. 2003;49:417–423.
   PubMed Web of Science ®Google Scholar
• Iacobellis G, Pond CM, Sharma AM. Different “weight” of cardiac and general adiposity in predicting left ventricle morphology. Obesity (Silver Spring). 2006;14:1679–1684.
   PubMed Web of Science ®Google Scholar
• Marchington JM, Pond CM. Site-specific properties of pericardial and epicardial adipose tissue: the effects of insulin and high-fat feeding on lipogenesis and the incorporation of fatty acids in vitro. Int J Obes. 1990;14:1013–1022.
   PubMed Web of Science ®Google Scholar
• Iacobellis G. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11:363–371.
   PubMed Web of Science ®Google Scholar
• Balsaver AM, Morales AR, Whitehouse FW. Fat infiltration of myocardium as a cause of cardiac conduction defect. Am J Cardiol. 1967;19:261–265.
   PubMed Web of Science ®Google Scholar
• Goldberg IJ, Trent CM, Schulze PC. Lipid metabolism and toxicity in the heart. Cell Metab. 2012;15:805–812.
   PubMed Web of Science ®Google Scholar
• D’Souza K, Nzirorera C, Kienesberger PC. Lipid metabolism and signaling in cardiac lipotoxicity. Biochim Biophys Acta. 2016;1860:1513–1524.
   Web of Science ®Google Scholar
• Unger RH. Lipotoxic diseases. Annu Rev Med. 2002;53:319–336.
   PubMed Web of Science ®Google Scholar
• Fukushima A, Lopaschuk GD. Cardiac fatty acid oxidation in heart failure associated with obesity and diabetes. Biochim Biophys Acta. 2016;1860:1525–1534.
   Web of Science ®Google Scholar
• Tang H, Wang Y, Nicholson JK, et al. Use of relaxation-edited one-dimensional and two dimensional nuclear magnetic resonance spectroscopy to improve detection of small metabolites in blood plasma. Anal Biochem. 2004;325:260–272.
   PubMed Web of Science ®Google Scholar
• Tenori L, Hu X, Pantaleo P, et al. Metabolomic fingerprint of heart failure in humans: a nuclear magnetic resonance spectroscopy analysis. Int J Cardiol. 2013;168:e113–e115.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Cattaneo BM, et al. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25:560–563.
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Gorzelniak K, et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension. 2005;45:356–362.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Dell’Oro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension. 2000;36:538–542.
   PubMed Web of Science ®Google Scholar
• Grassi G, Seravalle G, Quarti-Trevano F, et al. Excessive sympathetic activation in heart failure with obesity and metabolic syndrome: characteristics and mechanisms. Hypertension. 2007;49:535–541.
   PubMed Web of Science ®Google Scholar
• Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169–2180.
   PubMed Web of Science ®Google Scholar
• Abed HS, Samuel CS, Lau DH, et al. Obesity results in progressive atrial structural and electrical remodeling: implications for atrial fibrillation. Heart Rhythm. 2013;10:90–100.
   PubMed Web of Science ®Google Scholar
• Kubota T, McTiernan CF, Frye CS, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627–635.
   PubMed Web of Science ®Google Scholar
• Koppo K, Siklova-Vitkova M, Klimcakova E, et al. Catecholamine and insulin control of lipolysis in subcutaneous adipose tissue during long-term diet-induced weight loss in obese women. Am J Physiol Endocrinol Metab. 2012;302:E226–E232.
   PubMed Web of Science ®Google Scholar
• Qi Z, Ding S. Obesity-associated sympathetic overactivity in children and adolescents: the role of catecholamine resistance in lipid metabolism. J Pediatr Endocrinol Metab. 2016;29:113–125.
   PubMed Web of Science ®Google Scholar
• Jocken JW, Blaak EE. Catecholamine-induced lipolysis in adipose tissue and skeletal muscle in obesity. Physiol Behav. 2008;94:219–230.
   PubMed Web of Science ®Google Scholar
• Frikke-Schmidt H, O’Rourke RW, Lumeng CN, et al. Does bariatric surgery improve adipose tissue function? Obes Rev. 2016;17:795–809.
   PubMed Web of Science ®Google Scholar
• Iso T, Arai M, Wada A, et al. Humoral factor(s) produced by pressure overload enhance cardiac hypertrophy and natriuretic peptide expression. Am J Physiol. 1997;273:H113–H118.
   PubMed Web of Science ®Google Scholar
• Hall C. NT-ProBNP: the mechanism behind the marker. J Card Fail. 2005;11:S81–S83.
   PubMed Web of Science ®Google Scholar
• Hammerer-Lercher A, Neubauer E, Muller S, et al. Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta. 2001;310:193–197.
   PubMed Web of Science ®Google Scholar
• Fisher C, Berry C, Blue L, et al. N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart. 2003;89:879–881.
   PubMed Web of Science ®Google Scholar
• Kovacova Z, Tharp WG, Liu D, et al. Adipose tissue natriuretic peptide receptor expression is related to insulin sensitivity in obesity and diabetes. Obesity (Silver Spring). 2016;24:820–828.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Larson MG, Levy D, et al. Impact of obesity on plasma natriuretic peptide levels. Circulation. 2004;109:594–600.
   PubMed Web of Science ®Google Scholar
• Daniels LB, Clopton P, Bhalla V, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the breathing not properly multinational study. Am Heart J. 2006;151:999–1005.
   PubMed Web of Science ®Google Scholar
• Asferg CL, Nielsen SJ, Andersen UB, et al. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension. 2013;62:147–153.
   PubMed Web of Science ®Google Scholar
• Martin J, Bergeron S, Pibarot P, et al. Impact of bariatric surgery on N-terminal fragment of the prohormone brain natriuretic peptide and left ventricular diastolic function. Can J Cardiol. 2013;29:969–975.
   PubMed Web of Science ®Google Scholar
• Cheng S, Fox CS, Larson MG, et al. Relation of visceral adiposity to circulating natriuretic peptides in ambulatory individuals. Am J Cardiol. 2011;108:979–984.
   PubMed Web of Science ®Google Scholar
• McMurray RW Jr., Vesely DL. Weight reduction decreases atrial natriuretic factor and blood pressure in obese patients. Metabolism. 1989;38:1231–1237.
   PubMed Web of Science ®Google Scholar
• Chainani-Wu N, Weidner G, Purnell DM, et al. Relation of B-type natriuretic peptide levels to body mass index after comprehensive lifestyle changes. Am J Cardiol. 2010;105:1570–1576.
   PubMed Web of Science ®Google Scholar
• Ahmad T, Fiuzat M, Mark DB, et al. The effects of exercise on cardiovascular biomarkers in patients with chronic heart failure. Am Heart J. 2014;167:193–202.
   PubMed Web of Science ®Google Scholar
• Bertoni AG, Wagenknecht LE, Kitzman DW, et al. Impact of the look AHEAD intervention on NT-pro brain natriuretic peptide in overweight and obese adults with diabetes. Obesity (Silver Spring). 2012;20:1511–1518.
   PubMed Web of Science ®Google Scholar
• Taner ED, Yavuz B, Okhan AK, et al. An obesity drug sibutramine reduces brain natriuretic peptide (BNP) levels in severely obese patients. Int J Clin Pract. 2010;64:518–522.
   PubMed Web of Science ®Google Scholar
• St Peter JV, Hartley GG, Murakami MM, et al. B-type natriuretic peptide (BNP) and N-terminal pro-BNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem. 2006;52:680–685.
   PubMed Web of Science ®Google Scholar
• Abrahamsson N, Engstrom BE, Sundbom M, et al. Gastric bypass surgery elevates NT-ProBNP levels. Obes Surg. 2013;23:1421–1426.
   PubMed Web of Science ®Google Scholar
• Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324–331.
   PubMed Web of Science ®Google Scholar
• Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation. 2007;116:627–636.
   PubMed Web of Science ®Google Scholar
• Gupta A, Braunwald E, McNulty S, et al. Obesity and the response to intensified diuretic treatment in decompensated heart failure: a DOSE trial substudy. J Card Fail. 2012;18:837–844.
   PubMed Web of Science ®Google Scholar
• Gaddam KK, Ventura HO, Lavie CJ. Metabolic syndrome and heart failure–the risk, paradox, and treatment. Curr Hypertens Rep. 2011;13:142–148.
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Sharma A, Alpert MA, et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis. 2016;58:393–400.
   PubMed Web of Science ®Google Scholar
• Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115:1428–1434.
   PubMed Web of Science ®Google Scholar
• Clark AL, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2014;56:409–414.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63:2985–3023.
   PubMed Web of Science ®Google Scholar
• Falken Y, Hellstrom PM, Holst JJ, et al. Changes in glucose homeostasis after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one year after surgery: role of gut peptides. J Clin Endocrinol Metab. 2011;96:2227–2235.
   PubMed Web of Science ®Google Scholar
• Borg CM, Le Roux CW, Ghatei MA, et al. Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut adaptation and explains altered satiety. Br J Surg. 2006;93:210–215.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683–2693.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Gummesson A, Sjostrom CD, et al. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol. 2009;10:653–662.
   PubMed Web of Science ®Google Scholar
• Sjostrom L, Narbro K, Sjostrom CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–752.
   PubMed Web of Science ®Google Scholar
• Garza CA, Pellikka PA, Somers VK, et al. Structural and functional changes in left and right ventricles after major weight loss following bariatric surgery for morbid obesity. Am J Cardiol. 2010;105:550–556.
   PubMed Web of Science ®Google Scholar
• Owan T, Avelar E, Morley K, et al. Favorable changes in cardiac geometry and function following gastric bypass surgery: 2-year follow-up in the Utah obesity study. J Am Coll Cardiol. 2011;57:732–739.
   PubMed Web of Science ®Google Scholar
• Valezi AC, Machado VH. Morphofunctional evaluation of the heart of obese patients before and after bariatric surgery. Obes Surg. 2011;21:1693–1697.
   PubMed Web of Science ®Google Scholar
• Popescu WM, Bell R, Duffy AJ, et al. A pilot study of patients with clinically severe obesity undergoing laparoscopic surgery: evidence for impaired cardiac performance. J Cardiothorac Vasc Anesth. 2011;25:943–949.
   PubMed Web of Science ®Google Scholar
• Masoomi H, Buchberg B, Reavis KM, et al. Factors predictive of venous thromboembolism in bariatric surgery. Am Surg. 2011;77:1403–1406.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Gupta H, Kaushik M, et al. Predictors of pulmonary complications after bariatric surgery. Surg Obes Relat Dis. 2012;8:574–581.
   PubMed Web of Science ®Google Scholar
• Benotti P, Wood GC, Winegar DA, et al. Risk factors associated with mortality after Roux-en-Y gastric bypass surgery. Ann Surg. 2014;259:123–130.
   PubMed Web of Science ®Google Scholar
• Leichman JG, Wilson EB, Scarborough T, et al. Dramatic reversal of derangements in muscle metabolism and left ventricular function after bariatric surgery. Am J Med. 2008;121:966–973.
   PubMed Web of Science ®Google Scholar
• Ippisch HM, Inge TH, Daniels SR, et al. Reversibility of cardiac abnormalities in morbidly obese adolescents. J Am Coll Cardiol. 2008;51:1342–1348.
   PubMed Web of Science ®Google Scholar
• Mukerji R, Petruc M, Fresen JL, et al. Effect of weight loss after bariatric surgery on left ventricular mass and ventricular repolarization in normotensive morbidly obese patients. Am J Cardiol. 2012;110:415–419.
   PubMed Web of Science ®Google Scholar
• Algahim MF, Lux TR, Leichman JG, et al. Progressive regression of left ventricular hypertrophy two years after bariatric surgery. Am J Med. 2010;123:549–555.
   PubMed Web of Science ®Google Scholar
• Leichman JG, Aguilar D, King TM, et al. Improvements in systemic metabolism, anthropometrics, and left ventricular geometry 3 months after bariatric surgery. Surg Obes Relat Dis. 2006;2:592–599.
   PubMedGoogle Scholar
• Alsabrook GD, Goodman HR, Alexander JW. Gastric bypass for morbidly obese patients with established cardiac disease. Obes Surg. 2006;16:1272–1277.
   PubMed Web of Science ®Google Scholar
• Johnson BL, Blackhurst DW, Latham BB, et al. Bariatric surgery is associated with a reduction in major macrovascular and microvascular complications in moderately to severely obese patients with type 2 diabetes mellitus. J Am Coll Surg. 2013;216:545–556.
   PubMed Web of Science ®Google Scholar
• Miranda WR, Batsis JA, Sarr MG, et al. Impact of bariatric surgery on quality of life, functional capacity, and symptoms in patients with heart failure. Obes Surg. 2013;23:1011–1015.
   PubMed Web of Science ®Google Scholar
• Shimada YJ, Tsugawa Y, Brown DF, et al. Bariatric surgery and emergency department visits and hospitalizations for heart failure exacerbation: population-based, self-controlled series. J Am Coll Cardiol. 2016;67:895–903.
   PubMed Web of Science ®Google Scholar
• McCloskey CA, Ramani GV, Mathier MA, et al. Bariatric surgery improves cardiac function in morbidly obese patients with severe cardiomyopathy. Surg Obes Relat Dis. 2007;3:503–507.
   PubMed Web of Science ®Google Scholar
• Ramani GV, McCloskey C, Ramanathan RC, et al. Safety and efficacy of bariatric surgery in morbidly obese patients with severe systolic heart failure. Clin Cardiol. 2008;31:516–520.
   PubMed Web of Science ®Google Scholar
• Lim CP, Fisher OM, Falkenback D, et al. Bariatric surgery provides a “bridge to transplant” for morbidly obese patients with advanced heart failure and may obviate the need for transplantation. Obes Surg. 2016;26:486–493.
   PubMed Web of Science ®Google Scholar
• Vest AR, Patel P, Schauer PR, et al. Clinical and echocardiographic outcomes after bariatric surgery in obese patients with left ventricular systolic dysfunction. Circ Heart Fail. 2016;9:e002260.
   PubMed Web of Science ®Google Scholar
• Woods P, Paquette C, Martin J, et al. Metabolic and cardiovascular improvements after biliopancreatic diversion in a severely obese patient. Cardiovasc Diabetol. 2004;3:5.
   PubMed Web of Science ®Google Scholar
• Taylor TV, Bozkurt B, Shayani P, et al. End-stage cardiac failure in a morbidly obese patient treated by biliopancreatic diversion and cardiac transplantation. Obes Surg. 2002;12:416–418.
   PubMed Web of Science ®Google Scholar
• Ristow B, Rabkin J, Haeusslein E. Improvement in dilated cardiomyopathy after bariatric surgery. J Card Fail. 2008;14:198–202.
   PubMed Web of Science ®Google Scholar
• Gill RS, Karmali S, Nagandran J, et al. Combined ventricular assist device placement with adjustable gastric band (VAD-BAND): a promising new technique for morbidly obese patients awaiting potential cardiac transplantation. J Clin Med Res. 2012;4:127–129.
   PubMedGoogle Scholar
• Samaras K, Connolly SM, Lord RV, et al. Take heart: bariatric surgery in obese patients with severe heart failure. Two case reports. Heart Lung Circ. 2012;21:847–849.
   PubMed Web of Science ®Google Scholar
• Caceres M, Czer LS, Esmailian F, et al. Bariatric surgery in severe obesity and end-stage heart failure with mechanical circulatory support as a bridge to successful heart transplantation: a case report. Transplant Proc. 2013;45:798–799.
   PubMed Web of Science ®Google Scholar
• Jeng EI, Aranda JM Jr., Ahmed M, et al. Left ventricular assist device and bariatric surgery: a bridge to heart transplant by weight and waiting time reduction. J Card Surg. 2016;31:120–122.
   PubMed Web of Science ®Google Scholar
• Hoefnagel AL, Pasternak R, Curle AE, et al. Laparoscopic gastric bypass in a patient with an implanted left ventricular assist device. J Cardiothorac Vasc Anesth. 2012;26:880–882.
   PubMed Web of Science ®Google Scholar
• Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update–a consensus report from the pulmonary scientific council of the international society for heart and lung transplantation. J Heart Lung Transplant. 2006;25:745–755.
   PubMed Web of Science ®Google Scholar
• Vest AR, Wu Y, Hachamovitch R, et al. The heart failure overweight/obesity survival paradox: the missing sex link. JACC Heart Fail. 2015;3:917–926.
   PubMed Web of Science ®Google Scholar
• Lavie CJ, Ventura HO. The obesity paradox in heart failure: is it all about fitness, fat, or sex? JACC Heart Fail. 2015;3:927–930.
   PubMed Web of Science ®Google Scholar
• Perrone-Filardi P, Paolillo S, Costanzo P, et al. The role of metabolic syndrome in heart failure. Eur Heart J. 2015;36:2630–2634.
   PubMed Web of Science ®Google Scholar
• Pozzo J, Fournier P, Lairez O, et al. Obesity paradox: origin and best way to assess severity in patients with systolic HF. Obesity (Silver Spring). 2015;23:2002–2008.
   PubMed Web of Science ®Google Scholar
• Pandey A, Berry JD, Lavie CJ. Cardiometabolic disease leading to heart failure: better fat and fit than lean and lazy. Curr Heart Fail Rep. 2015;12:302–308.
   PubMedGoogle Scholar
• Gupta PP, Fonarow GC, Horwich TB. Obesity and the obesity paradox in heart failure. Can J Cardiol. 2015;31:195–202.
   PubMed Web of Science ®Google Scholar
• Wannamethee SG, Atkins JL. Muscle loss and obesity: the health implications of sarcopenia and sarcopenic obesity. Proc Nutr Soc. 2015;74:405–412.
   PubMed Web of Science ®Google Scholar
• Lavie CJ, De SA, Alpert MA, et al. Obesity paradox, cachexia, frailty, and heart failure. Heart Fail Clin. 2014;10:319–326.
   PubMed Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: an Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2016;68:1476–1488.
   PubMed Web of Science ®Google Scholar